The GA-VAX project, a collaboration between the German Center for Neurodegenerative Diseases (DZNE) and Intravacc B.V., is pioneering a first-in-class vaccine for C9orf72 ALS and FTD. Funded by the European Union’s EIC Transition Grant, GA-VAX aims to bring this groundbreaking therapy from preclinical development to first-in-human trials.

With strong preclinical efficacy, a scalable manufacturing process, and an upcoming GLP toxicology study, we are strategically positioned to initiate Phase 1b/2a clinical trials and, ultimately, progress toward market approval.

The German Center for Neurodegenerative Diseases (DZNE) and Intravacc B.V. have received funding from the European Union (EIC Transition Grant) for the pre-clinical development of a prototype vaccine for Amyotrophic Lateral Sclerosis (ALS) caused by the C9orf72 mutation, which also finds an application towards C9orf72 Frontotemporal Dementia (FTD). This project, known as GA-VAX, aims to develop the vaccine to a stage where it can be clinically tested in humans.

With promising preclinical results from efficacy studies available, we are moving towards a GLP toxicology study. This critical data will add to the overall package to have the vaccine candidate ready for a Phase 1b/2a clinical study.

We are actively seeking investors and strategic partners to support the clinical development of GA-VAX. There are several opportunities to get involved:

• Co-development Partnerships: Collaborate on clinical trials and commercialization
• Licensing Agreements: Secure exclusive rights to a first-in-class ALS/FTD vaccine
• Spin-off Creation: Invest in a biotech startup focused on neurodegenerative vaccine development

Your investment could accelerate the vaccine candidate to a Phase 1b/2a clinical trial in C9orf72 ALS/FTD patients. A successful Phase 2b clinical trial could allow direct entry into the orphan drug market.